Investor Presentaiton

Reported EBIT margin of 28%¹ in Q2, reflecting inflationary headwind on input costs, increased level of commercial activity, and amortisation costs Q2 2022/23 EBIT margin development before special items (%) 30.6 -2.3 -1.6 0.6 0.0 27.6 0.0 27.6 0.2 Reported EBIT margin Q2 A Gross Δ Δ Admin- A R&D- margin Distribution- to-sales to-sales to-sales A Other operating items 21/221 Reported EBIT margin Q1 22/231 Currency EBIT margin effect Q2 22/23 (Constant Currencies)1 1 Before special items of DKK 20 million in Q2 2022/23 related to integration costs for the Atos Medical acquisition, and DKK 381 million in Q2 21/22, of which DKK 300 million related to Mesh litigation provisions and the remaining DKK 81 million related to the Atos Medical acquisition (one-off transaction costs, legal and advisory fees) 12 Q2 2022/23 highlights Gross margin was 66%, against 69% in Q2 last year Negative impact from: input cost inflation (raw materials, energy, freight), double-digit wage inflation in Hungary, ramp-up costs in Costa Rica, and cost related to backorder resolution. Electricity price hedges of ~400 EUR/MWh (double from last year) took effect in January. Positive impact from: Atos Medical, price increases, country and product mix, and operating leverage and efficiency savings Limited positive FX impact on the gross margin of 30 bps Operating expenses in Q2 amounted to DKK 2,356 million. Operating expenses grew 8% from last year excl. inorganic operating expenses from Atos Medical (12% incl. inorganic OPEX). Atos Medical contributed with DKK 280 million, including DKK 53 million in amortisation costs. Distribution-to-sales ratio was 31%, compared to 29% last year Distribution costs were up 16% vs. last year, driven by Atos Medical, increased sales & marketing activities and travel post COVID-19, higher logistics costs, and continued commercial investments (Interventional Urology, consumer and digital, Atos Medical) The admin-to-sales ratio was 5%, on par with last year. The R&D-to- sales ratio was 3%, compared to 4% last year EBIT before special items was DKK 1,671 million, a 1% decrease from last year. Reported EBIT margin before special items was 28% compared to 31% last year (neutral impact from FX) Coloplast

View entire presentation